Klinische Studien auf der Basis molekularer Charakterisierung von Tumoren
Author:
Publisher
Springer Berlin Heidelberg
Link
https://link.springer.com/content/pdf/10.1007/978-3-662-46764-0_389-1
Reference219 articles.
1. Adams R, Brown E, Brown L, Butler R, Falk S, Fisher D, Kaplan R, Quirke P, Richman S, Samuel L, Seligmann J, Seymour M, Shiu KK, Wasan H, Wilson R, Maughan T, FOCUS4 Trial Investigators (2018) Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial. Lancet Gastroenterol Hepatol 3:162–171. https://doi.org/10.1016/S2468-1253(17)30394-1
2. Adams R, Fisher D, Graham J, Seligmann JF, Seymour M, Kaplan RS, Yates E, Richman SD, Quirke P, Butler R, Brown E, Falk S, Collinson FJ, Wilson RH, Brown LC, Maughan T, FOCUS4 Investigators (2021) Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: results from the randomized FOCUS4-N trial. J Clin Oncol 39(Suppl 15):abstr 3504. https://doi.org/10.1200/JCO.2021.39.15_suppl.3504
3. Aggarwal C, Redman MW, Lara PN Jr, Borghaei H, Hoffman P, Bradley JD, Newman AJ 3rd, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR (2019) SWOG S1400D (NCT02965378), a phase II study of the fibroblast growth factor receptor inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway-activated stage IV squamous cell lung cancer (Lung-MAP substudy). J Thorac Oncol 14:1847–1852. https://doi.org/10.1016/j.jtho.2019.05.041
4. Ahlborn LB, Rohrberg KS, Gabrielaite M, Tuxen IV, Yde CW, Spanggaard I, Santoni-Rugiu E, Nielsen FC, Lassen U, Mau-Sorensen M, Østrup O (2019) Application of cell-free DNA for genomic tumor profiling: a feasibility study. Oncotarget 10:1388–1398. https://doi.org/10.18632/oncotarget.26642
5. Ahn ER, Mangat PK, Garrett-Mayer E, Halabi S, Dib EG, Haggstrom DE, Alguire KB, Alvarez RH, Calfa CJ, Cannon TL, Crilley PA, Gaba AG, Marr AS, Sangal A, Thota R, Antonelli KR, Islam S, Rygiel AL, Bruinooge SS, Schilsky RL (2019) Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J Clin Oncol 37(Suppl):abstr 9041. https://doi.org/10.1200/JCO.2019.37.15_suppl.9041
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3